Watch NKTR. Know when insiders buy.
One email the day a filing lands. Free.
Work order
52
WATCH · insiders 48, shorts 55
Insiders, 90 days
−$43K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.5BP/E —DIV YIELD —FCF YIELD -9.24%REV TTM $54.6M −27.2%NET INCOME −$157.1MNET DEBT $94.2M52W 35.12 – 100.35SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $10.1M | −9.3% | — | −$42.3M | −$40.6M | — | -1.23 | −$75.8M | $94K | −$75.9M | Aug 14 |
| Q1 2026 · Mar 31 | $10.9M | +3.8% | — | −$39.1M | −$44.9M | — | -1.82 | −$44.3M | $18K | −$44.3M | May 8 |
| Q4 2025 · Dec 31derived | $21.8M | −25.3% | 100.0% | −$27.7M | −$36.1M | −596.9% | -1.59 | −$65M | $18K | −$65M | Mar 13 |
| Q3 2025 · Sep 30 | $11.8M | −51.1% | 100.0% | −$31.7M | −$35.5M | — | -1.87 | −$48.8M | $114K | −$48.9M | Nov 7 |
| Q2 2025 · Jun 30 | $11.2M | −52.4% | 100.0% | −$36.2M | −$41.6M | — | -2.95 | −$45.7M | $37K | −$45.8M | Aug 14 |
| Q1 2025 · Mar 31 | $10.5M | −51.7% | 100.0% | −$44.5M | −$50.9M | — | -3.62 | −$49.1M | $2K | −$49.1M | May 8 |
| Q4 2024 · Dec 31derived | $29.2M | +22.1% | 72.7% | $14.3M | $7.3M | — | 0.59 | −$46.2M | $459K | −$46.6M | Mar 13 |
| Q3 2024 · Sep 30 | $24.1M | −0.1% | 81.6% | −$34.3M | −$37.1M | — | -2.66 | −$43.9M | $666K | −$44.6M | Nov 7 |
| Q2 2024 · Jun 30 | $23.5M | — | 58.5% | −$49.8M | −$52.4M | — | -3.76 | −$37.7M | $186K | −$37.9M | Aug 8 |
| Q1 2024 · Mar 31 | $21.6M | — | 60.6% | −$35.4M | −$36.8M | — | -0.19 | −$47.9M | $157K | −$48M | May 9 |
| Q4 2023 · Dec 31derived | $23.9M | — | 69.5% | −$33.5M | −$42.1M | — | -0.22 | −$47M | $237K | −$47.3M | Mar 14 |
| Q3 2023 · Sep 30 | $24.1M | — | 48.5% | −$44.9M | −$45.8M | — | -0.24 | −$42.1M | $33K | −$42.2M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $55.2M | 100.0% | −$140.1M | −$164.1M | -297.1% | -9.73 | −$208.5M | $171K | −$208.7M | $0 | — |
| FY2024 · to Dec 31 | $98.4M | 68.8% | −$105.2M | −$119M | -120.9% | -8.68 | −$175.7M | $1.5M | −$177.2M | $3M | — |
| FY2023 · to Dec 31 | $90.1M | 62.5% | −$263.7M | −$276.1M | -306.3% | -1.45 | −$192.6M | $865K | −$193.5M | $0 | — |
| FY2022 · to Dec 31 | $92.1M | 76.5% | −$376.2M | −$368.2M | -400.0% | -1.97 | −$304M | $5.7M | −$309.7M | — | — |
| FY2021 · to Dec 31 | $101.9M | 75.6% | −$446.1M | −$523.8M | -514.0% | -2.86 | −$412.7M | $15M | −$427.6M | — | — |
| FY2020 · to Dec 31 | $152.9M | 87.3% | −$425.1M | −$444.4M | -290.6% | -2.49 | −$313.3M | $7.3M | −$320.5M | — | — |
Every number comes from NEKTAR THERAPEUTICS's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.